Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance

Yang, Lu; Li, Ningwei; Wang, Hongjing; Jia, Xibiao; Wang, Handong; Luo, Juan

doi:10.3892/or.2012.1823

Cited by 110 publications

(69 citation statements)

References 43 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no significant differences between the two groups in terms of gender, age, international prognostic index (IPI) and stage. We investigated the pretreatment concentrations of serum miR-155, miR-200c, miR-29c, miR-130a, miR-145, miR-451, miR-125b and miR-21 expression levels, which have been reported in certain other tumor types to be associated with chemotherapy resistance (Table III) (9,14,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29). We observed that only the expression of miR-130a and miR-125b was correlated significantly with the response to chemotherapy.…”

Section: Dysregulated Expression Profiles Of Eight Mirnas In Dlbclmentioning

confidence: 90%

“…A number of previous studies have revealed that miRNAs are involved in the progress of drug resistance in certain types of cancer (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29). These miRNAs might play a crucial role in drug resistance by targeting their specific genes.…”

mentioning

confidence: 99%

“…Zhang et al (26) reported that low miR-130a expression led to a significant upregulation in the XIAP mRNA levels, which further resulted in the development of ovarian cancer cell resistance to cisplatin. However, Yang et al (28) provided the adverse conclusion that low miR-130a restrains MDR1 mRNA/P-glycoprotein, which plays a repressive role in the ABC superfamily drug transporters and the drug resistance pathways of PI3k/AKT/PTEN/mTOR. Similarly, upregulated miR-130a expression was also detected in the drug-resistant group in the present study.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients

Yuan

Gui

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Numerous studies have reported the aberrant expression profiles of microRNAs (miRNAs) in diffuse large B-cell lymphoma (DLBCL), although very few of these studies were concerned with chemoresistance to R-CHOP in DLBCL patients. This study was designed to assess the correlation between circulating miRNA expression and chemoresistance and prognosis in DLBCL patients. At the start of the study, we demonstrated that miRNA expression levels in serum were significantly associated with those in formalin-fixed, paraffin-embedded tissues, which indicated that circulating miRNAs may be powerful, non-invasive biomarkers reflecting miRNAs levels isolated from tumor tissue. Then from eight potential drug-resistant miRNAs which were deregulated in DLBCL and which had been reported to be associated with drug resistance in other carcinomas, we screened out the circulating miR-125b and miR-130a, which may related to R-CHOP resistance. Dynamic monitoring of the levels of circulating miR-125b and miR-130a further demonstrated that they were involved in recurrence, progression and chemoresistance in DLBCL patients. Finally, we demonstrated that high miR-125b indicated poor prognosis, as patients with higher miR-125b levels had a shorter overall survival. To our knowledge, this is the first study demonstrating that miR-125b and miR-130a are associated with the risk of chemoresistance in DLBCL patients, and that dynamic monitoring of the levels of circulating miR-125b and miR-130a predicts the therapeutic response and disease status of DLBCL patients.

show abstract

Section: Dysregulated Expression Profiles Of Eight Mirnas In Dlbclmentioning

confidence: 90%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients

Yuan

Gui

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…But the role of miR-130a in cancer drug resistance remains controversial. Yang et al [26] found that downregulation of miR-130a could inhibit MDR1 mRNA and P-gp expression, and overcome the cisplatin resistance in SKOV3/CIS cells. In this study, we found that miR-130a was down-regulated in the cisplatin-resistant A2780/DDP cells when compared with its corresponding cisplatinsensitive parental cell lines by qRT-PCR.…”

Section: Discussionmentioning

confidence: 99%

Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly

Zhang¹,

Huang²,

Zhao³

et al. 2013

ABBS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short, highly conserved small non-coding RNA molecules, which post-transcriptionally regulate genes expression and play crucial roles in diverse biological processes. Recent studies have shown that dysregulation of miRNAs might modulate the resistance of cancer cells to chemotherapeutic agents. To investigate the possible role of miR-130a in the development of cisplatin resistance in human ovarian cancer cell line A2780, we evaluated the expression of microRNA-130a (miR-130a) in the cells by the quantitative real-time reverse transcriptionpolymerase chain reaction. The results showed that miR130a was significantly down-regulated in cisplatin-resistant ovarian cancer cells. MTT assay and flow cytometry (FCM) results showed that over-expression of miR-130a regulated apoptotic activity, and thereby cisplatin chemosensitivity, in ovarian cancer cells. Furthermore, we found that miR-130a can directly target XIAP, and participate in the regulation of apoptosis. The up-regulation of miR-130a led to a significant decrease in the XIAP mRNA levels and protein levels. XIAP plays an important role in cisplatin resistance in ovarian cancer cell line A2780. Our findings suggested that miR-130a could play a role in the development of cisplatin resistance in ovarian cancer cell line A2780, at least in part by modulation of apoptosis via targeting XIAP.

show abstract

“…Indeed, Garofalo et al (2012) found that some miRNAs, such as miR-221, miR-222, and miR-30, are associated with gefitinib resistance in NSCLC cell lines by targeting the proteins which contribute to drug resistance. Some researchers have also shown that miR-130a contributes to multidrug resistance in human hepatocellular carcinoma (HCC) and ovarian cancer (Xu et al, 2012;Yang et al, 2012). However, to date there have been no reports concerning the role of miR-130a in gefitinib resistance in NSCLC.…”

Section: Introductionmentioning

confidence: 99%

MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines

Zhou

Liu²,

Sun³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the most common cause of lung cancer death. Currently, the epidermal growth factor receptor inhibitor gefitinib is used for its treatment; however, drug resistance is a major obstacle. Expression of Met has been associated with both primary and acquired resistance to gefitinib, but the mechanisms regulating its expression are not fully understood. Recently, miRNAs such as miR-130a have been shown to play a role in gefitinib resistance, but importance in NSCLC and relationships with Met have not been fully explored. Here we show that miR-130a is over-expressed in gefitinibsensitive NSCLC cell lines, but is low in gefitinib-resistant NSCLC cell lines. Moreover, miR-130a expression was negatively correlated with that of Met. Further analysis revealed that over-expression of miR-130a increased cell apoptosis and inhibited proliferation of NSCLC cells treated with gefitinib, whereas lowering the expression of miR-130a decreased cell apoptosis and promoted cell proliferation after treatment with gefitinib in both gefitinib-sensitive and -resistant NSCLC cell lines, suggesting that miR-130a overcomes gefitinib resistance. We also demonstrated that miR-130a binds to the 3'-UTR of Met and significantly suppresses its expression. Finally, our results showed that over-expressing Met could "rescue" the functions of miR-130a regarding cell apoptosis and proliferation after cells are treated with gefitinib. These findings indicate that the miR-130a/Met axis plays an important role in gefitinib resistance in NSCLC. Thus, the miR-130a/Met axis may be an effective therapeutic target in gefitinib-resistant lung cancer patients.

show abstract

Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance

Cited by 110 publications

References 43 publications

Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients

Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients

Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly

MiR-130a Overcomes Gefitinib Resistance by Targeting Met in Non-Small Cell Lung Cancer Cell Lines

Contact Info

Product

Resources

About